AZD2962
A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)
What will happen during the trial?
This is a modular study. In Module 1, the study will begin with a dose escalation of AZD2962 monotherapy in participants with myelodysplastic syndromes (MDS) and dysplastic chronic myelomonocytic leukemia (CMML).
Module 1 of the study will comprise of:
A Screening Period of maximum 21 days.
Treatment period with 28-day cycles where each patient will receive an oral dose of AZD2962 once daily, starting on Day 1, and will continue treatment until disease progression, unacceptable toxicity, or withdrawal.
Safety Follow-up period after 30 days after last dose.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 72 patients (estimated)
- Sponsors
- AstraZeneca
- Collaborators
- Parexel
- Tags
- IRAK 4 Inhibitor
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2192
- NCT Identifier
- NCT07064122
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.